Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15-year experience at a single Institute

Journal of Surgical Oncology

Volumn 95, Issue 6, 2007, Pages 461-468

  Byoung, Chul Cho ^a,b,c   Hei, Cheul Jeung ^a,b,c   Hye, Jin Choi ^a,b,c   Sun, Young Rha ^a,b,c   Woo, Jin Hyung ^b   Jae, H Cheong ^b   Sung, Hoon Noh ^b   Hyun, Cheol Chung ^a,b,c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Extended gastrectomy; Gastric cancer; Prognosis; Resection margin

Indexed keywords

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GASTRECTOMY; HISTOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; REOPERATION; STOMACH CANCER; SURVIVAL TIME;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEMALE; FLUOROURACIL; GASTRECTOMY; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; MALE; MIDDLE AGED; MITOMYCIN; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 34248172027     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.20731     Document Type: Article

References (26)

1. Alberts SR, Cervantes A, van de Velde CJH. Gastric cancer: Epidemiology, pathology and treatment. Ann Oncol 2003;14: ii31-36.
2. Maehara Y, Baba H, Sugimachi K. Adjuvant chemotherapy for gastric cancer: A comprehensive review. Gastric Cancer 2001;4: 175-184.
3. Nakamura K, Ueyama T, Yao T, et al.: Pathology and prognosis of gastric cancer: Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992;70:1030-1037.
4. Hyung WJ, Lee JH, Choi SH, et al.: Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol 2002;9:562-567.
5. Kim SW, Rha KH, Rheu CH, et al.: Clinicopathologic significance of lymphatic vessel invasion and blood vessel invasion in gastric cancer. J Korean Cancer Assoc 1999;31:16-23.
6. Kooby DA, Suriawinata A, Klimstra DS, et al.: Biologic predictors of survival in node-negative gastric cancer. Ann Surg 2003;237:828-837.
7. Wanebo HJ, Kennedy BJ, Chmiel H, et al.: Cancer of the stomach. A patient care study by the American College of Surgeons. Ann Surg 1993;218:583-592.
8. Songun I, Bonenkamp JJ, Hermans J, et al.: Prognostic value of resection-line involvement in patients undergoing curative resections for gastric cancer. Eur J Cancer 1996;32:433-437.
9. Kim SH, Karpeb MS, Klimstra DS, et al.: Effect of microscopic resection line disease on gastric cancer survival. J Gastrointest Surg 1999;3:24-33.
10. Hallissey MT, Jewkes AJ, Dunn JA, et al.: Resection-line involvement in gastric cancer: A continuing problem. Br J Surg 1993;80:1418-1420.
11. Cascinu S, Giordani P, Catalano V, et al.: Resection-line involvement in gastric cancer patients undergoing curative resections: Implications for clinical management. Jpn J Clin Oncol 1999;29:291-293.
12. Yokota T, Sawai K, Yamaguchi T, et al.: Resection margin in patients with gastric cancer associated with esophageal invasion: Clinicopathological study. J Surg Oncol 1993;53: 60-63.
13. Papachristou DN, Agnanti N, D'Agostino H, et al.: Histologically positive esophageal margin in the surgical treatment of gastric cancer. Am J Surg 1980;139:711-713.
14. Adam IJ, Mohamdee MO, Martin IG, et al.: Role of circumferential margin involvement in the local recurrence of rectal cancer. Lancet 1994;344:707-711.
15. Dexter SP, Sue-Ling H, McMahon MJ, et al.: Circumferential resection margin involvement: An independent predictor of survival following surgery for oesophageal cancer. Gut 2001; 48:667-670.
16. Yoo CH, Noh SH, Shin DW, et al.: Recurrence following curative resection for gastric carcinoma. Br J Surg 2000;87:236-242.
17. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: Areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982;8:1-11.
18. Roukos DH, Lorenz M, Encke A. Evidence of survival benefit of extended (D2) lymphadenectomy in western patients with gastric cancer based on a new concept: A prospective long-term follow-up study. Surgery 1998;123:573-578.
19. Sierra A, Regueira FM, Hernandez-Lizoain JL, et al.: Role of the extended lymphadenectomy in gastric cancer surgery: Experience in a single institution. Ann Surg Oncol 2003;10: 219-226.
20. Sano T, Sasako M, Yamamoto S, et al.: Gastric cancer surgery: Morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy-Japan Clinical Oncology Group Study 9501. J Clin Oncol 2004;22:2767-2773.
21. Hundahl SA. Staging, stage migration and patterns of spread in gastric cancer. Semin Radiat Oncol 2002;12:141-149.
22. Sano T, Mudan SS. No advantage of reoperation for positive resection margins in node positive gastric cancer patients? Jpn J Clin Oncol 1999;29:283-284.
23. Kasakura Y, Fujii M, Mochizuki F, et al.: Clinicopathological features of the superficial spreading type of early gastric cancer. Gastric Cancer 1999;2:129-135.
24. Matsusaka S, Nagareda T, Yamasaki H, et al.: Immunohistochemical evaluation for intraoperative rapid pathological assessment of the gastric margin. World J Surg 2003;27:715-718.
25. Jeung HC, Rha SY, Noh SH, et al.: Adjuvant 5-ftuorouracil plus doxorubicin in D2-3 resected gastric carcinoma. 15-Year Experience at a single Institute. Cancer 2001;91:2016-2025.
26. Moertel CG, Childs DS Jr, Reitemeier RJ, et al.: Combined 5-ftuorouracil and super-voltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet 1969;2:865-867.